Core Insights - The latest net value of Zhongyin Innovation Medical Mixed A Fund (007718) is 2.2349 CNY, reflecting a decline of 1.45% [1] - The fund has shown a one-month return of 20.54%, ranking 164 out of 4631 in its category; a six-month return of 88.98%, ranking 20 out of 4484; and a year-to-date return of 85.73%, ranking 27 out of 4447 [1] Fund Holdings - The top ten stock holdings of Zhongyin Innovation Medical Mixed A Fund account for a total of 62.83%, with the following allocations: - Innovent Biologics (8.33%) - Kelun-Biotech (8.15%) - Hengrui Medicine (8.08%) - CanSino Biologics (8.07%) - Sinovac Biotech (6.13%) - Baillie Gifford (5.99%) - BeiGene (5.97%) - Hansoh Pharmaceutical (4.15%) - Rongchang Biologics (4.05%) - CanSino-B (3.91%) [1] Fund Manager Profile - Zheng Ning, the fund manager of Zhongyin Innovation Medical Mixed A Fund, has a background in finance with a master's degree and has held positions at various asset management companies, including as a stock research manager at Taikang Asset Management and a senior researcher at Zhonggeng Fund Management [2] - Zheng Ning has been managing the Zhongyin Innovation Medical Mixed A Fund since July 1, 2022, and has also taken on management roles for other funds within the company [2]

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong Stock Connect Innovative Drug ETF (159570), which has seen significant inflows and a record scale of over 11.8 billion yuan [1][3] - The ETF's trading volume exceeded 1.6 billion yuan in a single day, with a net inflow of over 390 million yuan yesterday and an additional 145 million yuan during the day [1] - The ETF's underlying index consists of leading innovative drug companies, with significant gains observed in stocks such as Kanglong Chemical, Innovent Biologics, and WuXi AppTec [3][4] Group 2 - Innovent Biologics' dual-target PD-1/IL-2 therapy IBI363 has received approval for two clinical trials, one of which will advance to frontline treatment for lung cancer, indicating strong potential in the oncology space [3] - The recent ASCO conference showcased promising survival data for IBI363 in colorectal cancer and non-small cell lung cancer, generating positive expectations within the industry [3] - The eleventh batch of drug procurement has been initiated, emphasizing the encouragement of innovation and the establishment of transparent selection rules for drug procurement [5][6] Group 3 - The innovative drug sector is viewed as a key investment theme, with expectations for continued growth and performance in the second quarter [5] - The new procurement rules aim to protect innovative drugs by excluding them from collective procurement during the negotiation period, thereby fostering a more favorable environment for innovation [6] - The market is anticipated to experience a rotation, with undervalued assets likely to see a new round of valuation increases, particularly in the context of AI healthcare opportunities [6][7]

Group 1 - The core viewpoint of the news highlights the strong performance of the Hong Kong innovative drug sector, with the Hong Kong Stock Connect Innovative Drug ETF (520880) reaching a historical high, increasing by 4.18% [1] - The Hong Kong Stock Connect Innovative Drug ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which has seen a year-to-date increase of 107.56%, outperforming other innovative drug indices [2][3] - Major stocks in the innovative drug sector, such as Innovent Biologics, CSPC Pharmaceutical Group, and WuXi AppTec, have shown significant gains, with Innovent Biologics rising over 3% and others increasing by more than 1% [1][2] Group 2 - Analysts indicate that the innovative drug sector remains a clear trend within the pharmaceutical industry, with substantial growth potential and attractive valuations, suggesting increased foreign investment in Hong Kong innovative drugs [4] - The performance of the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has varied over the years, with historical declines in 2021, 2022, 2023, and 2024, but the current year shows a strong recovery [3]

Group 1 - The Hong Kong stock market's innovative drug sector is experiencing significant growth, with the Hong Kong Stock Connect Innovative Drug ETF (520880) rising by 4.18%, reaching a new historical high [1] - The ETF has a premium rate exceeding 3%, indicating strong buying interest, with a trading volume surpassing 200 million yuan [1] - The Hang Seng Hong Kong Stock Connect Innovative Drug Select Index has increased by 107.56% year-to-date, outperforming other innovative drug indices [1] Group 2 - WuXi AppTec reported a revenue of 20.799 billion yuan for the first half of the year, reflecting a year-on-year growth of 20.64%, with net profit attributable to shareholders increasing by 95.5% to 8.287 billion yuan [2] - The global pharmaceutical transaction volume reached 456 deals in the first half of the year, with a total upfront payment of 11.8 billion USD and a total transaction value of 130.4 billion USD, showing significant increases in both quantity and value [2] - Transactions involving China contributed nearly 50% of the total transaction value and over 30% of the total number of deals [2]

Group 1 - The Hong Kong Innovative Drug ETF (513120) reached a record size of 16.12 billion yuan as of July 29, 2025, with a year-to-date growth of 111.29%, making it the top-performing pharmaceutical ETF in Hong Kong [1] - The CSI Hong Kong Innovative Drug Index (931787) surged by 3.85% on July 29, 2025, with notable increases in constituent stocks such as WuXi AppTec (02359) up 10.76% and Innovent Biologics (01801) up 8.77% [1] - The ETF's liquidity was strong, with a turnover rate of 74.62% and a total trading volume of 11.64 billion yuan on July 29, 2025, leading the market in pharmaceutical ETFs [1] Group 2 - The CSI Hong Kong Innovative Drug Index tracks up to 50 listed companies involved in innovative drug research and development, with a significant focus on biopharmaceuticals and chemical pharmaceuticals, which together account for 92.5% of the index [2] - As of June 30, 2025, the top ten weighted stocks in the index accounted for 67.94%, including companies like Innovent Biologics (01801) and WuXi Biologics (02269) [2] Group 3 - In the first half of 2025, global pharmaceutical transactions reached 456, a 32% year-on-year increase, with total upfront payments soaring by 136% to 11.8 billion USD [3] - Chinese companies contributed nearly 50% of the total transaction value and over 30% of the transaction volume in the global innovative drug market [3] - On July 28, 2025, Heng Rui Medicine announced a deal with GSK for the global exclusive rights to the HRS-9821 project, with an upfront payment of 500 million USD and potential milestone payments totaling around 12 billion USD [3] Group 4 - On July 25, 2025, the National Healthcare Security Administration held a meeting to discuss new policies supporting innovative drugs and medical devices, aiming to accelerate the clinical application of high-level technological innovations [4] - China’s innovative drug assets are gaining global recognition, with increasing business development (BD) licensing amounts and numbers, indicating a growing global influence [4] - The Hong Kong Innovative Drug ETF (513120) supports T+0 trading, allowing investors to trade multiple times within a trading day, enhancing liquidity and capital efficiency [4]

Investment Rating - The investment rating for the biotechnology industry is "Positive" (maintained) [1] Core Insights - The global stock of multiple sclerosis (MS) patients is significant, with the market size exceeding $20 billion, primarily focused on relapsing forms of MS (RMS) [6][9] - BTK inhibitors are expected to fill the treatment gap in primary progressive MS (PPMS) and non-relapsing secondary progressive MS (nrSPMS) [7][9] - The anticipated release of clinical data for BTK inhibitors in the second half of 2025 is expected to enhance the attractiveness of the sector [9] Summary by Sections 1. Multiple Sclerosis Overview - MS is an immune-mediated inflammatory demyelinating disease of the central nervous system, characterized by "spatial" and "temporal" multiplicity [5][27] - The global and Chinese stock of MS patients is projected to reach 3.71 million and 60,000 respectively by 2030, with a CAGR of approximately 2.7% and 2.1% from 2025 to 2030 [19][22] 2. Market Size and Product Landscape - The global MS market is approximately $20 billion, with a focus on RMS treatments [6][40] - Existing products include monoclonal antibodies and oral therapies, with CD20 monoclonal antibodies expected to account for over 60% of sales by 2024 [6][46] 3. BTK Inhibitors and Clinical Development - BTK inhibitors are positioned to address unmet needs in the treatment of PPMS and nrSPMS, with several candidates in late-stage clinical trials [7][51] - Tolebrutinib and Fenebrutinib are expected to release pivotal clinical data in the second half of 2025, which could significantly impact their market potential [8][51] 4. Investment Recommendations - The ongoing clinical developments and the large patient base present significant investment opportunities in companies like 诺诚健华, 翰森制药, 云顶新耀, 恒瑞医药, and 百济神州-U [9]

2）创新药出海带动研发链需求。2025年Q1中国创新药License-out交易33笔，总金额超362亿美元（同比 +258%），恒瑞医药、翰森制药等与默沙东、诺和诺德达成重磅合作（单笔首付达2亿美元），本土创 新药国际化加速，直接拉动CRO临床前及生产服务需求。 药明康德近日公告，上半年净利润85.61亿元，同比增长101.92%，计划每10股派发现金红利3.5元（含 税）。公司预计2025年整体收入从人民币415-430亿元上调至人民币425-435亿元。 光大证券指出，药明康德作为CRO行业龙头，交出"史上最强"半年报，显示出行业需求的强劲。其收入 上调预期，表明业务拓展顺利，对CRO行业有积极示范效应。 从行业来看，CRO行业正在迎来三大复苏信号： 1）全球外包渗透率提升。全球药企研发成本攀升推动外包需求，2025年上半年，国内CRO企业普遍呈 现订单高增、产能扩张的态势；药明康德上调收入指引，验证行业需求确定性。 本文源自：金融界 3）政策与资本双支撑。国内医保局推动创新药审评审批提速，欧美暂缓《生物安全法案》至2032年， 地缘政治风险短期缓和，利好创新药行业。 展望后市，CRO、CDMO板块自2 ...

Core Viewpoint - Southbound capital has significantly increased its investment in the Hong Kong stock market this year, leading to a historical net inflow of over 840 billion HKD, surpassing previous records and contributing to a strong performance in the market [1][2]. Group 1: Southbound Capital Inflows - As of July 29, 2023, southbound capital has recorded a cumulative net inflow of 8420.02 billion HKD, marking a historical high for the year and more than double the inflow of the same period in 2024 [1][2]. - The daily net inflow peaked on April 9, 2023, with 355.86 billion HKD, setting a record for single-day inflows [1]. - In 135 trading days this year, there were net inflow days on 114 occasions, accounting for over 80% of the trading days [1]. Group 2: Market Performance - The Hang Seng Index has risen over 27% year-to-date, while the Hang Seng Technology Index has increased by over 26% [1][3]. - Major stocks with market capitalizations exceeding 1 trillion HKD have all seen gains, with Xiaomi Group-W up over 60% and Tencent Holdings up over 34% [1][4]. - The Hong Kong stock market has outperformed major global markets, with the Hang Seng Index, Hang Seng China Enterprises Index, and Hang Seng Technology Index showing respective increases of 27.24%, 25.46%, and 26.33% [3]. Group 3: Sector and Stock Performance - Southbound capital has heavily invested in the financial, information technology, and consumer discretionary sectors, with holdings valued at 14517.43 billion HKD, 11115.84 billion HKD, and 7175.67 billion HKD respectively [2][3]. - Notable individual stock holdings include Tencent Holdings at over 5400 billion HKD, and other significant investments in China Mobile, Xiaomi Group-W, and Alibaba-W, each exceeding 2000 billion HKD [2][3]. Group 4: Valuation and Future Outlook - The rolling P/E ratio of the Hang Seng Index has increased to 10.49 times, up from 8.96 times at the beginning of the year, indicating a rise in market valuation [5][6]. - Analysts predict that southbound capital inflows could exceed 1 trillion HKD for the year, although the pace may slow in the second half [6][7]. - The overall market sentiment remains positive, with expectations of continued upward movement supported by improved fundamentals and ongoing capital inflows [6][7].

Group 1 - The Hong Kong Innovation Drug ETF (513120) has seen a strong increase of 3.37%, marking a four-day consecutive rise, with significant gains in constituent stocks such as Green Leaf Pharmaceutical (02186) up 8.50% and WuXi AppTec (02359) up 7.97% [1] - The ETF's trading volume was active, with a turnover of 31.99% and a total transaction value of 4.947 billion [1] - The ETF's latest scale reached 15.136 billion, a new high in nearly a year, ranking first among Hong Kong pharmaceutical ETFs [1] Group 2 - The CSI Hong Kong Innovation Drug Index (931787) closely tracks the performance of up to 50 listed companies involved in innovative drug research and development, with a significant weight of 92.5% in biopharmaceuticals and chemical pharmaceuticals [2] - As of June 30, 2025, the top ten weighted stocks in the index accounted for 67.94%, including companies like Innovent Biologics (01801) and WuXi Biologics (02269) [2] - WuXi AppTec reported a revenue of 20.799 billion, a year-on-year increase of 20.64%, with net profit rising by 101.92% to 8.56 billion [2] Group 3 - Heng Rui Medicine announced a licensing agreement with GSK for the global exclusive rights to the HRS-9821 project, receiving an upfront payment of 500 million and potential total payments of approximately 12 billion [3] - The total amount of overseas licensing transactions for innovative drugs in China increased by 26% in 2024, with over 2.5 billion in upfront payments in the first half of 2025 [3] - The Hong Kong Innovation Drug ETF supports T+0 trading, enhancing liquidity and capital efficiency for investors [3]

Group 1 - The core viewpoint of the news is that the Hong Kong innovative drug sector is experiencing significant growth, with the Hong Kong Stock Connect Innovative Drug ETF (520880) reaching a new historical high, reflecting strong investor interest and market momentum [1][4]. - The innovative drug sector has seen a year-to-date increase of 98.75% in the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, outperforming other indices significantly [4][5]. - Major companies in the sector, such as WuXi AppTec, have reported substantial revenue growth, with WuXi AppTec achieving a revenue of 20.799 billion yuan, a year-on-year increase of 20.6%, and a net profit of 8.287 billion yuan, up 95.5% [1][2]. Group 2 - Analysts believe that the current valuation of the innovative drug sector does not fully reflect its business development potential, with three major catalysts expected to support the sector's momentum in the second half of the year [2]. - Upcoming academic conferences, such as the World Lung Cancer Conference and the European Society for Medical Oncology Annual Meeting, are anticipated to showcase significant clinical research data from various companies, acting as direct catalysts for the sector [2]. - Active business development (BD) transactions are expected to continue, with recent successful licensing deals by companies like Hansoh Pharmaceutical and China Biologic Products, which not only generate direct revenue but also validate the R&D capabilities of Chinese pharmaceutical companies [2]. Group 3 - The Hang Seng Hong Kong Stock Connect Innovative Drug ETF (520880) passively tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Select Index, which focuses on the innovative drug R&D industry chain [2]. - As of the end of June, the top ten constituent stocks of the index accounted for 75.85% of the total weight, indicating a significant concentration of investment in leading companies [2][3]. - The index has shown a strong performance compared to other indices, with a notable excess return of 71.32% over the Hang Seng Index and 71.98% over the Hang Seng Tech Index [4].